Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

pressive team of multiple myeloma investigators in the Phase 1/2 trial, led by Dr. Richardson and Dr. Anderson. The updated overall response rate of 41%, an extended PFS, and median overall survival of 25 months particularly in a patient population where 73% were previously refractory to bortezomib, is highly encouraging. We look forward to starting the Phase 3 trial by year-end."

Keryx has been granted a Special Protocol Assessment (SPA) from the FDA for the Phase 3 study of perifosine in multiple myeloma. Additionally, the FDA has granted perifosine Orphan Drug and Fast Track designations in this indication.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About KRX-0401 (Perifosine)

KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, and a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... 17, 2014   MedeAnalytics today unveils ... brings complete visibility to a provider,s "mid-cycle" to ... reimbursement landscape. Powered by the industry,s leading big ... critical point between patient access and the business ... will improve revenue capture, minimize audit risk and ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Oct. 31, 2011 Covance Inc. (NYSE: ... ranked first, by a wide margin, in an independent ... trials. The majority (54 percent) of the study participants ... central laboratory, with investigators citing Covance three times more ...
... InterMune, Inc. (NASDAQ: ITMN ) today ... Shire plc, has been appointed to InterMune,s Board of ... on meeting the needs of the specialist physician. ... a leading global biopharmaceutical company with expertise in the ...
Cached Medicine Technology:Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 2Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 3InterMune Appoints Angus C. Russell to Board of Directors 2InterMune Appoints Angus C. Russell to Board of Directors 3
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... Cadiz Laser Spa offers the latest, most ... throughout Central Texas. The newest addition to their ... Using the revolutionary Rejuvapen micro-needling device Cadiz Laser ... a wide variety of skin issues. , The ... Spa is currently offering a special package through ...
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... a key factor to explain why antibiotic-resistant bacteria can thrive ... called plasmids appear to be the culprit. They can easily ... some carry a gene that makes bacteria drug-resistant, a new ... an antibiotic-resistant gene to a class of antibiotic called carbapenems," ...
(Date:9/17/2014)... might be able to reduce the need for invasive ... autoimmune disease lupus. , In a new study, researchers ... from nephritis kidney inflammation to interstitial fibrosis, ... A kidney biopsy is the only existing way to ... extent. , The model could also be used to ...
Breaking Medicine News(10 mins):Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2
... Corporation today announced it has requisitioned a special meeting ... return of capital to NUCRYST shareholders of approximately US$15 ... review alternatives to maximize the value of its 74.5 ... Corporations Act, NUCRYST,s Board of Directors has 20 days ...
... N.J., Dec. 1 ETHICON, Inc., a Johnson & ... of its Professional Wound Care business to One Equity Partners. ... , , Under the terms ... Wound Care product portfolio, which contains such advanced wound care ...
... Dec. 1 Democratic National Committee Chairman Howard Dean today ... 20th Anniversary: , , (Logo: ... "It,s been 20 years since the first World AIDS Day, ... be done to tackle this epidemic with both a national ...
... MassMutual Retirement Services Division has added two new ... has more than tripled in 2008 compared to last ... Dan Darby joined MassMutual on December 1 as nonprofit ... M. Palmer Whitney, national managing director, nonprofit market, for ...
... failure, study says , , MONDAY, Dec. 1 (HealthDay News) ... that cause idiosyncratic drug-induced liver injury (DILI), researchers say. ... cases of acute liver failure in the United States ... acute liver failure. , DILI is caused by a ...
... (PTSD) affects as many as one in five of all ... or terrorism. It has emotionally paralyzed survivors of 9/11 and ... accepted treatment that can lower the chance of developing the ... medical means of preventing PTSD may be just around the ...
Cached Medicine News:Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:Easing the stress of trauma 2
EPS 3501 : 3500 V, 150 mA, 100 W maximum. Constant voltage, constant current, or constant power modes. Stores and recalls three protocols. Excellent for manual DNA sequencing and IEF applications....
... power supply, with temperature probe, 100-120 and 220-240 ... 500 mA, and 400 W. The temperature probe ... and 90 degrees C during electrophoresis. Built-in infrared ... and instructions are provided. Dimensions are 27.5 x ...
... SPECIFICATIONS Form: Granular, free flowing powder EEO(-m r ): ... (3%): less than or equal to 31C Remelt ... Gel Strength (3%): greater than or equal to 500 ... equal to 1000 gm/cm 2 Moisture: less than ...
... chloride (Cl) ≤ 500 mg/kg sulfate (SO 4 ) ... Cd ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ... 10 mg/kg K ≤ 50 mg/kg Mg ≤ 50 ... Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ...
Medicine Products: